Swiss drugmaker Novartis
Like many pharmaceutical companies, Novartis is starting to face generic competition, with its breast cancer drug Femara and its blood pressure medicine Diovan losing patent protection.
A spokesman for Novartis said the firm could not confirm that number.
Novartis's local rival Roche
(Reporting by Catherine Bosley; Editing by John Stonestreet)
(Corrects headline and first paragraph to say job cuts have already been made)